References
- Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014; 157: 1262–1278.
- Jiang W, Marraffini LA. CRISPR-Cas: new tools for genetic manipulations from bacterial immunity systems. Annu Rev Microbiol. 2015; 69: 209–228.
- Makarova KS, Wolf YI, Alkhnbashi OS, et al. An updated evolutionary classification of CRISPR-Cas systems. Nat Rev Microbiol. 2015; 13: 722–736.
- Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014; 346: 1258096. 1355–1358
- Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012; 337: 816–821.
- Bialk P, Sansbury B, Rivera-Torres N, et al. Analyses of point mutation repair and allelic heterogeneity generated by CRISPR/Cas9 and single-stranded DNA oligonucleotides. Sci Rep. 2016; 6: 32681–32689.
- Richardson CD, Ray GJ, DeWitt MA, et al. Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. Nat Biotechnol. 2016; 34: 339–344.
- Woolf TM, Gurumurthy CB, Boyce F, Kmiec EB. To cleave or not to cleave: therapeutic gene editing with and without programmable nucleases. Nat Rev Drug Discov. 2017; 16(4): 296–299.
- Yáñez RJ, Porter AC. Therapeutic gene targeting. Gene Ther. 1998; 5: 149–159.
- Kmiec EB. Targeted gene repair. Gene Ther. 1999; 6: 1–3.
- Wollenberg D. CRISPR, genomics, and emerging disruption in the life sciences industry. Available online at: slalom.com/thinking/CRISPR-genomics-emerging-disruption-in-life-sciences-whitepaper. Last accessed November 6, 2018.
- Pardee K, Green AA, Takahashi MK, et al. Rapid, low-cost detection of Zika virus using programmable biomolecular components. Cell. 2016; 165: 1255–1266.
- Sansbury BM, Wagner AM, Nitzan E, et al. CRISPR-directed in vitro gene editing of plasmid DNA catalyzed by Cpf1 (Cas12a) nuclease and a mammalian cell-free extract. CRISPR J. 2018; 1(2): 191–202.
- Lin A, Giuliano CJ, Sayles NM, Sheltzer JM. CRISPR/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials. Elife. 2017; 6.
- Blighe K, DeDionisio L, Christie KA, et al. Gene editing in the context of an increasingly complex genome. BMC Genomics. 2018; 19(1): 595–615.
- Penn Medicine. FDA approves CAR T therapy for large B-cell lymphoma developed at Penn. Available online at: penntoday.upenn.edu/news/fda-approves-car-t-therapy-large-b-cell-lymphoma-developed-penn. Last accessed November 6, 2018.
- Ferrara L, Engstrom JU, Schwartz T, et al. Recovery of cell cycle delay following targeted gene repair by oligonucleotides. DNA Repair (Amst). 2007; 6: 1529–1535.
- Lu HY, Wang XJ, Mao WM. Targeted therapies in small cell lung cancer. Oncol Lett. 2013; 5: 3–11.
- Vogel KM. Crispr goes global: a snapshot of rules, policies, and attitudes. Bull At Sci. 2018. Available online at: thebulletin.org/2018/06/crispr-goes-global-a-snapshot-of-rules-policies-and-attitudes. Last accessed November 6, 2018.
- Kaiser J. U.S. panel gives yellow light to human embryo editing. Available online at: sciencemag.org/news/2017/02/us-panel-gives-yellow-light-human-embryo-editing. Last accessed November 6, 2018.